{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-097851","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2026-09-08T12:00:30+00:00","discovered_at":"2026-09-08T12:05:01.444391+00:00","generated_at":"2026-09-08T12:05:12.870837+00:00","sec_items":["8.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Relmada Therapeutics CMO – Urology Raj Pruthi departs effective Sept 3, 2026","bullets":["Dr. Raj S. Pruthi's employment as Chief Medical Officer – Urology ended on September 3, 2026.","No replacement or successor for the CMO – Urology role was named in the filing.","Departure was reported under Item 8.01; no reason or transition details provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-097851","json":"https://secwatch.observer/filing/0001213900-26-097851.json","markdown":"https://secwatch.observer/filing/0001213900-26-097851.md","text":"https://secwatch.observer/filing/0001213900-26-097851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026097851/0001213900-26-097851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390026097851/ea0304768-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T12:05:12.870837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}